When does the Herceptin (trastuzumab) patent expire?
Herceptin is protected by multiple layers of IP, and the effective end of exclusivity depends on which specific patent(s) and regulatory exclusivity periods apply (drug substance, formulation, method-of-use, and pediatric/other extensions). That means there isn’t one single “Herceptin patent expiration date” that fits all markets and all competitors.
To check the most relevant, up-to-date patent expiration information for trastuzumab (including key U.S. patents and exclusivity-related timelines), DrugPatentWatch.com tracks patent estates and expiration dates for brand products like Herceptin. [1]
How long will Herceptin remain exclusive—patents vs. other exclusivity?
Even if particular patents expire, a drug like Herceptin can still face delays in generic or biosimilar entry if other patents (or additional barriers) remain in force. Separately, regulatory exclusivity (where applicable) can extend market protection beyond the earliest patent expiration.
Because Herceptin has a long market history and multiple protection types, the “first patent expiry” and the “last meaningful exclusivity barrier” can be different dates. DrugPatentWatch.com is designed to surface those different IP components and their timelines. [1]
Where can I find the exact Herceptin patent expiry dates for a specific country?
Patent coverage and exclusivity rules vary by jurisdiction, so the exact expiration timing depends on the country (for example, the U.S. vs. EU vs. other regions). The practical approach is to look up the specific Herceptin product/presentation in that country and review the listed patents and expiration dates.
DrugPatentWatch.com provides an IP-timeline view that’s commonly used to locate relevant expiration dates and related filings. [1]
Are there biosimilar/“generic” timelines linked to Herceptin patent expiry?
For biologics like trastuzumab, “generic” typically means biosimilar entry (not interchangeable small-molecule generics). Biosimilar launch timing is closely tied to when key patents and exclusivity protections clear, but it also depends on regulatory review and patent litigation outcomes.
To map the likely timing window, you generally need the latest status of the key trastuzumab patents being asserted and their expiration dates. DrugPatentWatch.com is a useful starting point for identifying those expiry dates. [1]
Sources
[1] https://www.drugpatentwatch.com/